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Abstract The Gail model for predicting the absolute risk
of invasive breast cancer has been validated extensively in
US populations, but its performance in the international
setting remains uncertain. We evaluated the predictive
accuracy of the Gail model in 54,649 Spanish women aged
45–68 years who were free of breast cancer at the 1996–1998
baseline mammographic examination in the population-
based Navarre Breast Cancer Screening Program. Incident
cases of invasive breast cancer and competing deaths were
ascertained until the end of 2005 (average follow-up of
7.7 years) through linkage with population-based cancer and
mortality registries. The Gail model was tested for calibra-
tion and discrimination in its original form and after recali-
bration to the lower breast cancer incidence and risk factor
prevalence in the study cohort, and compared through cross-
validation with a Navarre model fully developed from this
cohort. The original Gail model overpredicted significantly
the 835 cases of invasive breast cancer observed in the cohort
(ratio of expected to observed cases 1.46, 95 % CI 1.36–
1.56). The recalibrated Gail model was well calibrated
overall (expected-to-observed ratio 1.00, 95 % CI 0.94–
1.07), but it tended to underestimate risk for women in low-
risk quintiles and to overestimate risk in high-risk quintiles
(P = 0.01). The Navarre model showed good cross-vali-
dated calibration overall (expected-to-observed ratio 0.98,
95 % CI 0.92–1.05) and in different cohort subsets. The
Navarre and Gail models had modest cross-validated dis-
crimination indexes of 0.542 (95 % CI 0.521–0.564) and
0.544 (95 % CI 0.523–0.565), respectively. Although the
original Gail model cannot be applied directly to populations
with different underlying rates of invasive breast cancer, it
can readily be recalibrated to provide unbiased estimates of
absolute risk in such populations. Nevertheless, its limited
discrimination ability at the individual level highlights the
need to develop extended models with additional strong risk
factors.
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Introduction
The Gail model for predicting the absolute risk of invasive
breast cancer in white women combined relative risks
associated to four traditional risk factors (age at menarche,
number of breast biopsies, age at first live birth, and
number of first-degree relatives with breast cancer) derived
from a case–control study conducted in the Breast Cancer
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Detection Demonstration Project [1] with baseline age-
specific incidence rates of invasive breast cancer from
population-based US cancer registries in the Surveillance,
Epidemiology, and End Results Program [2]. This predic-
tion model has been validated in several cohorts from the
United States, including large general populations [3–5],
regularly screened subpopulations at elevated risk [2–4],
and small studies in high-risk clinics [6, 7]. The Gail model
showed heterogeneous but generally acceptable calibration
with modest discrimination ability among white US
women [8], and it has been widely used to design inter-
national prevention trials [9, 10] and to counsel women
about their individual risk [11].
Few and relatively small validation studies have been
conducted in Western non-US populations, and none of
them used a population-based cohort design. In the United
Kingdom, the Gail model underestimated significantly
breast cancer risk in 3,150 women attending a family his-
tory clinic [12]. In Italy, the Gail model showed good
overall calibration but modest individual discrimination in
5,383 hysterectomized women enrolled in a breast cancer
chemoprevention trial [13] and, more recently, in 10,031
female volunteers with high prevalence of risk factors who
participated in the Florence cohort of the European Pro-
spective Investigation into Cancer and Nutrition study [14].
The Gail model could be useful to predict the risk of
developing invasive breast cancer in Spain, where all
women aged 50–69 years are currently covered by popu-
lation-based mammographic screening programs [15].
However, age-standardized breast cancer incidence rates in
Spain (61 cases per 100,000 women in 2008) are sub-
stantially lower than those in the United States (76) and
most countries in Northern (84), Western (90), and
Southern Europe (69) [16]. Thus, to avoid a systematic
overestimation of breast cancer risk among Spanish
women, it may be necessary to recalibrate the Gail model
for the different incidence rates of invasive breast cancer
and prevalences of risk factors in the Spanish population.
In this study, we evaluated the predictive accuracy of the
Gail model in its original form and after recalibration in a
large population-based cohort of women who participated
in the Navarre Breast Cancer Screening Program (NBCSP),
and compared its performance with that of a similar pre-
diction model fully developed from this Spanish cohort.
Methods
Navarre Breast Cancer Screening Program
The NBCSP belongs to the European Breast Cancer Net-
work and was the first population-based mammographic
screening program implemented in Spain in September
1990. The initial target population covered all women aged
45–65 years residing in the northern Spanish province of
Navarre, but this age range was extended to 69 years in
1998 (77,455 female inhabitants aged 45–69 years in
2001). The program achieved full coverage of the target
population in 2 years, the period established as the
screening interval. All performance indicators of the
NBCSP during the period 1990–2004, including a partici-
pation rate for first invitation of 84 % and an adherence to
successive invitations of 97 % [17], have consistently
exceeded the reference levels set by European guidelines
[18]. The population impact of the NBCSP on breast cancer
incidence and mortality rates in Navarre has recently been
reported [19, 20].
Study cohort, baseline assessment, and follow-up
A total of 62,909 women with no history of invasive or
in situ breast cancer who resided in Navarre and were born
between January 1, 1931 and December 31, 1952 were
invited to participate in the fourth screening round of the
fully consolidated NBCSP. Of these, 54,995 women agreed
to participate and were mammographically screened
between September 1996 and July 1998 (participation rate
87.4 %).
Baseline information on age at menarche, previous
breast biopsy, number of births, age at first live birth, and
number of first-degree relatives (mother or sisters) with
breast cancer was obtained from structured questionnaires
administered by trained interviewers in the fourth screen-
ing round. Most women who reported ever having a breast
biopsy referred to tests performed outside the NBCSP, and
hence we were unable to determine the precise number of
previous breast biopsies. Also, atypical hyperplasia was
only ascertained in a small subset of women with biopsies
performed within the NBCSP and, therefore, not consid-
ered in risk predictions.
For the present study, we excluded 168 women with
prevalent breast cancer at their baseline mammographic
examination in the fourth screening round, as well as 3
women who developed breast cancer and 35 women who
died within 180 days from baseline. We also excluded 113
women lost to follow-up after baseline examination and 27
women with missing baseline information on the required
risk factors. Thus, the starting cohort consisted of 54,649
women aged 45–68 years who were followed for the period
beginning 180 days after the 1996–1998 baseline exami-
nation through December 31, 2005. Breast cancer cases
were ascertained through linkage with the population-
based Navarre Cancer Registry [21], which records all
incident cases of invasive or in situ breast cancer diagnosed
since 1973 in women residing in Navarre. Case ascertain-
ment during follow-up was likely to be complete, since the
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registry searched all relevant case sources in addition to the
NBCSP, with 99 % of breast cancer cases histologically
verified and 0.8 % registered solely on the basis of death
certificates in 1998–2002 [22]. Deaths from other causes
were identified through the Navarre Mortality Registry,
which includes all deaths registered in Spain among resi-
dents in Navarre. The municipal register of inhabitants and
the regional health system were consulted to confirm that
disease-free women were still living in Navarre at the end
of follow-up. Only 292 women were lost to follow-up and
censored at the time of their last visit to the NBCSP, while
the remaining women were followed disease free through
December 31, 2005.
During an average follow-up of 7.7 years, 835 cases of
invasive breast cancer, 150 cases of ductal carcinoma
in situ, and 2 cases of non-epithelial breast tumor were
diagnosed. In addition, 1,218 other women died from
causes not related to breast cancer. Hormone receptor
status could be determined from pathology reports in 767
of the 835 invasive breast cancers (91.9 %), with 653
tumors positive for either estrogen (634) or progesterone
receptors (486) and 114 tumors negative for both receptors.
Statistical analysis
The baseline hazards and hazard ratios of invasive breast
cancer in the NBCSP cohort were estimated from a
piecewise exponential model [23] with constant baseline
hazards in each 5-year age interval from 45 to 74 years and
the same ordinal risk factors as the original Gail model [1],
except for the simpler never/ever classification for previous
breast biopsy. In particular, the risk factors included in this
model were age at menarche (coded as 0, 1, or 2 for C14,
12–13, or \12 years, respectively), previous breast biopsy
(coded as 0 if no and 1 if yes), age at first live birth (coded
as 0, 1, 2, or 3 for \20, 20–24, 25–29 or nulliparous, or
C30 years, respectively), and number of first-degree rela-
tives with breast cancer (coded as 0, 1, or 2 for 0, 1, or C2
affected relatives, respectively). The model also included
interaction terms between age at first birth and number of
affected relatives and between breast biopsy and age
(coded as 0 if \50 and 1 if C50 years), so that the hazard
ratio for breast biopsy was allowed to vary from age
intervals below to those above 50 years. A detailed justi-
fication and specification of this model is provided in the
statistical appendix (Supplementary Material 1). The
composite hazards of death from other causes were cal-
culated by dividing the observed number of deaths in the
NBCSP cohort by the woman-years at risk in each 5-year
age interval.
Following standard competing risk methods [1, 23],
three alternative models were used to predict the absolute
risk of invasive breast cancer for each NBCSP woman
according to their own risk factor profile. The Navarre
model was based on baseline hazards and hazard ratios of
invasive breast cancer estimated from the above piecewise
exponential model in the NBCSP cohort, as well as on
composite hazards of competing death among NBCSP
women. The original Gail model used Gail relative risk
estimates [1] and invasive breast cancer and mortality rates
for white US women [2], whereas the recalibrated Gail
model combined the original relative risk estimates [1]
with composite incidence rates of invasive breast cancer,
composite mortality rates, and risk factor prevalences
among cases from the NBCSP cohort. The Gail relative
risk for women with any previous breast biopsy was cal-
culated as a weighted average of the reported relative risks
[1] for one and two or more biopsies. Further details on the
development of these prediction models are provided in the
statistical appendix (Supplementary Material 1).
Calibration and discrimination of the three prediction
models among NBCSP women were evaluated through a
10-fold cross-validation to correct for the optimistic bias
induced by testing the Navarre model on the same training
NBCSP data [24]. Calibration was assessed by comparing
the observed cases of invasive breast cancer in the NBCSP
cohort by age interval, risk factor category, and quintile of
predicted 5-year risk with those expected under the Nava-
rre, original Gail, and recalibrated Gail models [25]. Dis-
crimination was evaluated using overall and age-specific
C indexes [26], which are extensions of the area under the
receiver-operating curve to censored time-to-event data.
The discrimination ability of the Gail model remained
unchanged after recalibration. Further details on cross-val-
idated calibration and discrimination statistics are provided
in the statistical appendix (Supplementary Material 1).
Results
Cause-specific hazards and hazard ratios from NBCSP
cohort
The hazard of invasive breast cancer was higher in NBCSP
women with previous benign breast biopsies, and it
increased with decreasing age at menarche and with
increasing age at first live birth and number of affected
first-degree relatives. These hazard ratios were similar in
direction but lower in magnitude than those from the Gail
model, particularly for the strata of age at first birth by
number of affected relatives (Table 1). Contrary to the Gail
model, there was no significant interaction between breast
biopsy and age (P = 0.97) or between age at first birth and
number of affected relatives (P = 0.23). The population
attributable risk for all four factors was 0.280 and varied
little with age.
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The baseline hazards of invasive breast cancer from the
NBCSP cohort increased steadily in screened women aged
45–64 years and declined in unscreened older women. These
baseline incidence rates were similar to those derived from
the Navarre Cancer Registry, except that the latter also
included prevalent cases aged 45–49 years detected at their
first participation in the NBCSP (Table 2). The composite
mortality rates from other causes in the NBCSP cohort
increased sharply with age but were 18.8 % [standardized
mortality ratio 0.812, 95 % confidence interval (CI)
0.768–0.859] lower than those registered in the entire female
population of Navarre (Table 2), suggesting that self-
selected women in the NBCSP cohort were somewhat
healthier than the general female population.
Calibration of prediction models
The Navarre model showed good cross-validated calibration
overall (ratio of expected to observed cases 820.1/
835 = 0.98, 95 % CI 0.92–1.05), as well as across categories
of age at menarche (goodness-of-fit P = 0.42), breast biopsy
by age (P = 0.99), and age at first birth by number of
affected relatives (P = 0.95). The original Gail model
overestimated significantly the absolute risk of invasive
Table 1 Hazard ratios of invasive breast cancer by risk factor category in the Navarre Breast Cancer Screening Program cohort, 1996–1998 to
2005










Age at menarche (years)
C14 23,530 181,394 335 1.00 (reference) 1.00 (reference)
12–13 25,198 193,970 413 1.07 (0.97–1.19) 1.10 (1.02–1.19)
\12 5,921 45,436 87 1.15 (0.94–1.41) 1.21 (1.03–1.41)
Previous breast biopsy
Age \50 years
No 12,289 29,166 42 1.00 (reference) 1.00 (reference)
Yes 1,221 2,950 7 1.65 (0.74–3.67) 1.89 (1.50–2.38)c
Age C50 years
No 49,562 353,410 673 1.00 (reference) 1.00 (reference)
Yes 4,966 35,274 113 1.67 (1.37–2.04) 1.36 (1.19–1.56)c
No. of affected first-degree relatives
Age at first live birth \20 years
0 983 7,593 10 1.00 (reference) 1.00 (reference)
1 47 370 1 0.92 (0.45–1.87) 2.61 (1.99–3.42)
C2 1 8 0 0.84 (0.20–3.51) 6.80 (3.96–11.68)
Age at first live birth 20–24 years
0 15,377 118,331 204 1.11 (1.01–1.23) 1.24 (1.16–1.33)
1 879 6,746 12 1.26 (0.81–1.95) 2.68 (2.23–3.22)
C2 36 264 1 1.42 (0.62–3.28) 5.78 (4.14–8.06)
Age at first live birth 25–29 years or nulliparous
0 27,437 211,445 434 1.24 (1.01–1.52) 1.55 (1.35–1.78)
1 1,696 12,975 39 1.72 (1.28–2.32) 2.76 (2.32–3.27)
C2 108 810 2 2.39 (1.48–3.88) 4.91 (3.76–6.41)
Age at first live birth C30 years
0 7,575 58,382 116 1.38 (1.02–1.88) 1.93 (1.56–2.38)
1 491 3,726 16 2.36 (1.51–3.67) 2.83 (2.22–3.62)
C2 19 150 0 4.02 (1.82–8.88) 4.17 (2.75–6.31)
a Hazard ratios (HRs) and 95 % confidence intervals (CIs) of invasive breast cancer estimated from the Navarre Breast Cancer Screening
Program (NBCSP) cohort by fitting a piecewise exponential model with the same risk factors and ordinal codes as the original Gail model
b Odds ratios (ORs) and 95 % confidence intervals (CIs) of invasive or in situ breast cancer derived from the original Gail logistic model in the
Breast Cancer Detection Demonstration Project case–control study [1]
c The age-specific odds ratios of breast cancer for women with any previous breast biopsy were calculated by combining the age-specific odds
ratios for women with one and two or more biopsies reported in the original Gail model [1] (see statistical appendix in Supplementary Material 1)
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breast cancer in the NBCSP cohort by 46 % (expected-to-
observed ratio 1215.5/835 = 1.46, 95 % CI 1.36–1.56),
with greater overprediction in the older age intervals
(Table 3). This systematic overestimation disappeared after
recalibrating the Gail model (expected-to-observed ratio
836.4/835 = 1.00, 95 % CI 0.94–1.07), with no significant
lack of fit across the three risk factor categorizations
(P = 0.48, 0.36, and 0.15, respectively).
The median predicted 5-year risks of invasive breast
cancer were 0.93, 1.31, and 0.95 % under the Navarre,
original Gail, and recalibrated Gail models, respectively,
with 2.9, 25.6, and 4.1 % of NBCSP women above the
standard risk threshold of 1.67 %. The Navarre model
showed good agreement between observed and expected
cases by quintile of predicted 5-year risk (goodness-of-fit
P = 0.36). The original Gail model overpredicted signifi-
cantly invasive breast cancer cases in all quintiles of risk
(Table 4). The recalibrated Gail model corrected this sys-
tematic overprediction (goodness-of-fit P = 0.25), but due
to the larger Gail relative risks, it still showed a significant
positive trend in the expected-to-observed ratios across
quintiles of risk (P for linear trend = 0.01).
Discrimination of prediction models
Overall, the cross-validated discrimination indexes among
NBCSP women were modest and equal to 0.542 (95 % CI
0.521–0.564) for the Navarre model and 0.544 (95 % CI
0.523–0.565) for the Gail model, with no significant
difference between models (P = 0.67). Discrimination
remained similar in age intervals below 70 years and
increased marginally to 0.628 for the Navarre model and
0.626 for the Gail model among women aged 70–74 years
(P for deviation from overall discrimination = 0.09 and
0.08, respectively; Table 5).
The cross-validated discrimination indexes were some-
what better for hormone receptor-positive invasive breast
cancers (0.545, 95 % CI 0.521–0.569, for the Navarre
model and 0.543, 95 % CI 0.519–0.567, for the Gail
model) than for hormone receptor-negative cancers (0.508,
95 % CI 0.446–0.571, and 0.530, 95 % CI 0.469–0.591,
respectively).
Discussion
The original Gail model overestimated the actual invasive
breast cancer incidence by 46 % in a large population-
based cohort of biennially screened Spanish women aged
45–68 years who were followed for an average of
7.7 years. The recalibrated Gail model was well calibrated
overall, but it still underestimated breast cancer risk for
women with a low risk-factor profile and overestimated
risk for women with a high risk-factor profile. The Navarre
model showed good cross-validated calibration overall and
in different cohort subsets. Nevertheless, both the Navarre
and Gail models had limited discrimination ability of 0.54
in this cohort.
Table 2 Age-specific incidence rates of invasive breast cancer and mortality rates from other causes (per 100,000 woman-years) in the Navarre
Breast Cancer Screening Program cohort, 1996–1998 to 2005
Age (years) No. of
woman-years














45–49 32,116 49 111.3 (77.4–160.1) 156.6 34 105.9 (75.6–148.2) 115.2
50–54 96,663 185 138.9 (108.1–178.4) 134.8 151 156.2 (133.2–183.2) 166.6
55–59 100,953 202 144.0 (112.2–184.9) 146.4 204 202.1 (176.2–231.8) 239.7
60–64 86,085 193 160.4 (124.4–206.9) 175.9 241 280.0 (246.8–317.6) 327.8
65–69 77,621 166 152.8 (117.3–199.1) 146.2 373 480.5 (434.2–531.9) 619.5
70–74 27,362 40 104.3 (71.3–152.4) 114.1 215 785.8 (687.4–898.1) 1085.2
a Baseline incidence rates of invasive breast cancer and 95 % confidence intervals (CIs) for a woman at the reference level of all risk factors (age
at menarche C14 years, no previous breast biopsy, age at first live birth \20 years, and no affected first-degree relatives) estimated from a
piecewise exponential model in the Navarre Breast Cancer Screening Program (NBCSP) cohort
b External baseline incidence rates of invasive breast cancer for a woman at the reference level of all risk factors (age at menarche C14 years, no
previous breast biopsy, age at first live birth \20 years, and no affected first-degree relatives) calculated as the composite incidence rates of
invasive breast cancer for the period 2000–2004 obtained from the Navarre Cancer Registry multiplied by one minus the overall attributable risk
estimated from the Navarre Breast Cancer Screening Program cohort
c Composite mortality rates from other causes and 95 % confidence intervals (CIs) among women in the Navarre Breast Cancer Screening
Program (NBCSP) cohort
d External composite mortality rates from other causes in the entire female population of Navarre during the period 2000–2004 obtained from the
Spanish National Institute of Statistics
Breast Cancer Res Treat (2013) 138:249–259 253
123
Table 3 Ratios of the expected cases of invasive breast cancer under the Navarre, original Gail, and recalibrated Gail prediction models to the



































45–49 49 48.87 1.00 (0.75–1.32) 61.60 1.26 (0.95–1.66) 50.81 1.04 (0.78–1.37)
50–54 185 182.97 0.99 (0.86–1.14) 208.61 1.13 (0.98–1.30) 183.01 0.99 (0.86–1.14)
55–59 202 198.90 0.98 (0.86–1.13) 268.34 1.33 (1.16–1.52) 201.40 1.00 (0.87–1.14)
60–64 193 189.49 0.98 (0.85–1.13) 281.55 1.46 (1.27–1.68) 194.40 1.01 (0.87–1.16)
65–69 166 161.72 0.97 (0.84–1.13) 292.15 1.76 (1.51–2.05) 167.14 1.01 (0.86–1.17)
70–74 40 38.14 0.95 (0.70–1.30) 103.24 2.58 (1.89–3.52) 39.61 0.99 (0.73–1.35)
Age at menarche (years)
C14 335 339.14 1.01 (0.91–1.13) 508.56 1.52 (1.36–1.69) 341.86 1.02 (0.92–1.14)
12–13 413 385.28 0.93 (0.85–1.03) 567.08 1.37 (1.25–1.51) 395.11 0.96 (0.87–1.05)
\12 87 95.68 1.10 (0.89–1.36) 139.86 1.61 (1.30–1.98) 99.41 1.14 (0.93–1.41)
Previous breast biopsy
Age \50 years
No 42 41.84 1.00 (0.74–1.35) 51.60 1.23 (0.91–1.66) 42.56 1.01 (0.75–1.37)
Yes 7 7.03 1.00 (0.48–2.11) 10.00 1.43 (0.68–3.00) 8.25 1.18 (0.56–2.47)
Age C50 years
No 673 660.74 0.98 (0.91–1.06) 1016.75 1.51 (1.40–1.63) 691.11 1.03 (0.95–1.11)
Yes 113 110.48 0.98 (0.81–1.18) 137.14 1.21 (1.01–1.46) 94.45 0.84 (0.70–1.01)
No. of affected first-degree relatives
Age at first live birth \20 years
0 10 11.85 1.18 (0.64–2.20) 13.60 1.36 (0.73–2.53) 9.60 0.96 (0.52–1.78)
1 1 0.54 0.54 (0.10–21.35) 1.72 1.72 (0.31–67.95) 1.25 1.25 (0.22–49.28)
C2 0 0.01 – 0.12 – 0.06 –
Age at first live birth 20–24 years
0 204 206.10 1.01 (0.88–1.16) 259.50 1.27 (1.11–1.46) 185.37 0.91 (0.79–1.04)
1 12 13.47 1.12 (0.64–1.98) 31.98 2.67 (1.51–4.69) 22.84 1.90 (1.08–3.35)
C2 1 0.61 0.61 (0.11–23.98) 2.60 2.60 (0.47–102.68) 1.87 1.87 (0.34–73.89)
Age at first live birth 25–29 years or nulliparous
0 434 409.97 0.94 (0.86–1.04) 600.26 1.38 (1.26–1.52) 411.27 0.95 (0.86–1.04)
1 39 35.33 0.91 (0.66–1.24) 66.61 1.71 (1.25–2.34) 45.08 1.16 (0.84–1.58)
C2 2 3.11 1.55 (0.43–12.83) 7.50 3.75 (0.94–14.99) 5.03 2.52 (0.63–10.06)
Age at first live birth C30 years
0 116 124.45 1.07 (0.89–1.29) 210.19 1.81 (1.51–2.17) 139.99 1.21 (1.01–1.45)
1 16 13.77 0.86 (0.53–1.41) 20.11 1.26 (0.77–2.05) 13.23 0.83 (0.51–1.35)
C2 0 0.90 – 1.30 – 0.78 –
Overall 835 820.10 0.98 (0.92–1.05) 1215.49 1.46 (1.36–1.56) 836.37 1.00 (0.94–1.07)
To correct for the optimistic bias induced by assessing calibration of the Navarre prediction model on the same data used to fit the model, a 10-fold cross-validation
was used in which the absolute risk of invasive breast cancer for women in each 10 % random subcohort was calculated based on cause-specific hazards and hazard
ratios estimated from the remaining 90 % of women in the Navarre Breast Cancer Screening Program cohort (see statistical appendix in Supplementary Material 1)
a The Gail prediction model was tested for calibration in its original form, which combined the original relative risk estimates [1] with invasive breast cancer and
mortality rates for white women in the United States [2], and after recalibration, which combined the original relative risk estimates [1] with cross-validated
estimates of composite invasive breast cancer and mortality rates and risk factor prevalences among cases from the Navarre Breast Cancer Screening Program cohort
(see statistical appendix in Supplementary Material 1)
b The expected number of invasive breast cancer cases for a given age interval or risk factor category was calculated as the sum of the individual absolute risks of
invasive breast cancer predicted by the models over that age interval or risk factor category
c Ratios of expected to observed cases and 95 % confidence intervals (CIs) assuming a negligible variance for the expected number of cases and a Poisson variance
for the observed number of cases. If the expected number of cases was below 5, exact 95 % CIs were calculated based on a Poisson distribution
254 Breast Cancer Res Treat (2013) 138:249–259
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Comparison with other studies
Model calibration is strongly affected by temporal and
geographical variations in disease incidence. The Gail
model used invasive breast cancer rates among white US
women for the period 1983–1987 [2]. Since breast cancer
incidence increased steadily during the 1990 s in the Uni-
ted States [27], subsequent validation studies of the Gail
model resulted in overall underestimations of invasive
breast cancer risk by 6 % in the Nurses’ Health Study [3],
by 21 % in the Women’s Health Initiative [4], and by
13–14 % in two other recent US cohorts [5]. Thus, claims
have been raised about the need to update invasive breast
cancer rates used in the Gail model to ensure a good overall
calibration in recent US cohorts [3, 5, 28]. Our results
further highlight that, due to large worldwide variations in
breast cancer incidence [16], the Gail model should also be
recalibrated when applied to the international setting [29].
The lower breast cancer incidence rates in Spain compared
with the United States caused the Gail model to overesti-
mate breast cancer risk by 46 % in this Spanish cohort.
This systematic overprediction was corrected after recali-
brating the Gail model to the lower incidence rates and risk
factor prevalences in the study cohort.
The lower incidence of breast cancer in Spain can hardly
be explained by differences in regular mammography use
since its prevalence is similar in Spain (59 % of women aged
45 years or older in 2006) [30] and the United States (67 %
of women aged 40 years or older in 2005) [31]. The distri-
bution of Gail risk factors could better account for part of the
observed differences in countrywide rates, as women
younger than 12 years at menarche, with biopsy examina-
tions, and with affected first-degree relatives were half as
prevalent in the 1996–1998 baseline assessment of this
Spanish cohort as in concurrent assessments of large repre-
sentative US cohorts [4, 5]. Nevertheless, the baseline inci-
dence rates of invasive breast cancer for NBCSP women
aged 45–74 years were still 16 % lower than those used in
the Gail model [2], suggesting that other factors may con-
tribute to these differences. Obesity is more prevalent among
adult white US women [32] than their counterparts in Spain
[33]. Moreover, more than one-third of postmenopausal
women in the United States were taking hormone replace-
ment therapy between 1995 and 2001 [34], whereas this
therapy was rarely used in Spain [35].
The relative risks estimated from this Spanish cohort were
lower than those reported in the Gail model [1] which,
combined with the smaller risk factor prevalences, resulted
in an attributable risk of 0.28, substantially lower than the
value of 0.42 found in white US women [2]. The lower rel-
ative risks for age at menarche, age at first birth, and number
of affected relatives may be explained by the later age at
diagnosis of breast cancer cases: only 6 % of cases in our
cohort were diagnosed before 50 years of age, as opposed to
the 29 % enrolled in the Gail analysis [1]. There is com-
pelling evidence that reproductive [36] and familial factors
[37] have stronger effects on the risk of early-onset than late-
onset breast tumors. In fact, these risk factors showed con-
sistently weaker associations in three large US cohorts of
postmenopausal women [4, 5] than in the Gail model.
Clinical and public health implications and future
research
The less pronounced relative risks observed in this Spanish
population resulted in a modest discrimination of 0.54 for
both the Navarre and Gail models, somewhat lower than the
values of 0.58–0.59 reported for the Gail model among white
US [3–5] and Italian women [14]. Well-calibrated prediction
models with limited discrimination ability, such as the Na-
varre and recalibrated Gail models, may be useful in clinical
practice for counseling individual patients on the risks and
benefits of a preventive treatment [38], as well as for
designing adequately powered intervention trials. However,
higher discrimination is required for implementing an
effective prevention strategy in high-risk subsets of the
general population, in order to achieve large reductions in
disease incidence [39]. The inclusion of 7–18 common
genetic variants for breast cancer has been shown to increase
discrimination of the Gail model by 0.03–0.07 [40–42].
Apart from the substantial costs of obtaining genetic infor-
mation, this modest improvement in discrimination was
similar to the increase of 0.05 obtained from adding only
mammographic density, a strong and highly prevalent risk
factor [43]. A nested case–control study is currently being
conducted within the NBCSP to obtain mammographic
density measurements in nearly 1,000 incident cases of
invasive breast cancer and 4,000 disease-free women. This
case–control study might provide valuable data to improve
the discrimination accuracy of the Navarre model among
Spanish women by including mammographic density and
enhanced family history information on breast cancer.
Strengths and limitations of the study
The strengths of this study include the use of a large rep-
resentative cohort of regularly screened Spanish women,
the high participation rate, and the relatively long follow-
up period with negligible losses to follow-up, virtually
complete case ascertainment, and information on tumor
receptor status.
The study has several limitations. First, nearly all breast
cancer cases were diagnosed in women aged 50 years or
older, so our findings may not apply to younger pre-
menopausal women in regular screening. Second, infor-
mation on atypical hyperplasia was not available in 4,462
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of the 4,983 women with previous biopsy because they
referred to tests performed outside the NBCSP. Of the
remaining 521 women with biopsies performed within the
program, 16 had atypical hyperplasia. Thus, we can infer
that roughly 0.3 % of the entire NBCSP cohort had atypical
hyperplasia (3.1 % with atypia out of 9.1 % with biopsy)
and that the overall performance of the Navarre and Gail
models was little affected by knowledge of atypical
hyperplasia status. However, atypical hyperplasia is a
strong risk factor for breast cancer [44] and these models
will substantially underestimate breast cancer risk in
women with atypia, as has already been reported in other
cohorts [7]. Third, nondifferential misclassification of
baseline exposure [45] might have partially accounted for
the low relative risks and discrimination ability of the Gail
model in this Spanish cohort. Nevertheless, data were
collected from structured personal interviews and self-
reported Gail model variables, including family history of
breast cancer in first-degree relatives [46], are typically
accurate in this setting. Finally, cross-validation was used
to obtain overfitting-corrected estimates of the expected
internal validity of the Navarre model in new subjects from
the same population, but a more stringent external valida-
tion would be required in related but different populations.
Conclusions
The Gail model cannot be applied directly to populations
with different underlying rates of invasive breast cancer, but
it can readily be recalibrated to provide unbiased estimates of
absolute risk in these populations. In our study, the original
Gail model showed a substantial overestimation of breast
cancer risk that was corrected after recalibrating the model to
Table 4 Ratios of expected to observed cases of invasive breast cancer in the Navarre Breast Cancer Screening Program cohort by quintile of



















0.40–0.81 10,930 84,233 154 129.95 0.84 (0.72–0.99)
0.82–0.88 10,930 83,860 144 143.72 1.00 (0.85–1.18)
0.89–0.95 10,929 84,274 155 154.16 0.99 (0.85–1.16)
0.96–1.05 10,930 84,457 170 165.91 0.98 (0.84–1.13)
1.06–5.59 10,930 83,976 212 226.36 1.07 (0.93–1.22)
Original Gail prediction modela
0.54–0.96 10,930 84,783 126 151.09 1.20 (1.01–1.43)
0.97–1.18 10,931 84,260 156 190.94 1.22 (1.05–1.43)
1.19–1.44 10,927 84,287 173 229.06 1.32 (1.14–1.54)
1.45–1.74 10,931 84,041 175 273.13 1.56 (1.35–1.81)
1.75–7.70 10,930 83,429 205 371.28 1.81 (1.58–2.08)
Recalibrated Gail prediction modela
0.39–0.77 10,930 84,296 138 120.15 0.87 (0.74–1.03)
0.78–0.88 10,929 83,973 151 141.16 0.93 (0.80–1.10)
0.89–0.98 10,930 84,138 158 157.62 1.00 (0.85–1.17)
0.99–1.16 10,930 84,409 175 176.26 1.01 (0.87–1.17)
1.17–4.96 10,930 83,984 213 241.18 1.13 (0.99–1.30)
To correct for the optimistic bias induced by assessing calibration of the Navarre prediction model on the same data used to fit the model, a
10-fold cross-validation was used in which the absolute risk of invasive breast cancer for women in each 10 % random subcohort was calculated
based on cause-specific hazards and hazard ratios estimated from the remaining 90 % of women in the Navarre Breast Cancer Screening Program
cohort (see statistical appendix in Supplementary Material 1)
a The Gail prediction model was tested for calibration in its original form, which combined the original relative risk estimates [1] with invasive
breast cancer and mortality rates for white women in the United States [2], and after recalibration, which combined the original relative risk
estimates [1] with cross-validated estimates of composite invasive breast cancer and mortality rates and risk factor prevalences among cases from
the Navarre Breast Cancer Screening Program cohort (see statistical appendix in Supplementary Material 1)
b The expected number of invasive breast cancer cases in each quintile of predicted 5-year risk was calculated as the sum of the individual
absolute risks of invasive breast cancer predicted by the model over all women in that quintile
c Ratios of expected to observed cases and 95 % confidence intervals (CIs) assuming a negligible variance for the expected number of cases and
a Poisson variance for the observed number of cases
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the lower breast cancer incidence rates and risk factor
prevalences in this Spanish cohort. Nevertheless, the limited
discrimination ability of the Navarre and Gail models among
Spanish women precludes their use for screening applica-
tions and highlights the need to develop extended models
with additional strong risk factors, such as mammographic
density and detailed family history.
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